跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
鍾 禎智
助理教授
,
神經學科
主治醫師
,
衛生福利部雙和醫院
成員
,
臺北神經醫學中心
https://orcid.org/0000-0001-6743-6667
電子郵件
10670
s.tmu.edu
tw
h-index
668
引文
15
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2013
2024
每年研究成果
概覽
指紋
網路
專案
(4)
研究成果
(43)
資料集
(3)
類似的個人檔案
(6)
指紋
查看啟用 Chen-Chih Chung 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Neuroscience
Parkinson's Disease
100%
Artificial Neural Network
75%
Brain Ischemia
64%
Diabetes Mellitus
24%
Cognitive Disorders
20%
Cognitive Function
18%
Neurofilament Light Chain
18%
Amyloid
18%
Tissue Plasminogen Activator
17%
Magnetic Resonance Imaging
15%
Body Mass Index
14%
Hemoglobin A1c
11%
Synuclein
11%
Decision-Making
11%
Behavior (Neuroscience)
9%
Insulin-Like Growth Factor 1
9%
Retinal Disease
9%
Neuroscience
9%
Brain-Derived Neurotrophic Factor
9%
Synaptic Vesicle
9%
Diffusion Tensor Imaging
9%
Electroencephalography
9%
Meta-Analysis
9%
Randomized Controlled Trial
9%
Hypothermia
9%
Cerebral Hemorrhage
9%
Transverse Myelitis
9%
Myelitis
9%
Systemic Lupus Erythematosus
9%
Insulin Receptor
9%
Obstructive Sleep Apnea
9%
Interleukin 1
7%
Interleukin 6
6%
Necrosis
6%
Neuroprotective Agent
5%
Medicine and Dentistry
Brain Ischemia
52%
Parkinson's Disease
18%
Diabetes Mellitus
17%
Apoplexy
16%
Prognosis
15%
Sensitivity and Specificity
12%
Biological Marker
12%
Symptom
12%
Symptomatic Treatment
12%
Targeted Temperature Management
11%
Heart Arrest
11%
Maturity Onset Diabetes of the Young
10%
Atrial Fibrillation
10%
Antithrombotic
10%
Blood Clot Lysis
10%
National Institutes of Health Stroke Scale
10%
Disseminated Herpes Zoster
9%
Brain Infarction
9%
Transverse Myelitis
9%
Systematic Review
9%
Meta-Analysis
9%
Amyloid
9%
Tau
9%
Percutaneous Thrombectomy
9%
Heart Valve Bioprosthesis
9%
Prognostic Factor
9%
Procoagulant
9%
Warfarin
9%
Thrombectomy
9%
Valve Replacement
9%
Synuclein
9%
Ipilimumab
9%
Systemic Lupus Erythematosus
9%
Anticoagulant
9%
Nivolumab
9%
Non Small Cell Lung Cancer
9%
Myasthenia gravis
9%
Myositis
9%
Polyneuropathy
9%
Malignant Neoplasm
9%
Low and Middle Income Countries
9%
Cancer Control
9%
Cerebral Hemorrhage
7%
Cross-Validation
7%
Decision Making
7%
Pathognomonic
6%
Immune-Related Adverse Events
6%
Muscle Weakness
6%
Electromyography
6%
Dyspnea
6%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Ischemia
57%
Prognosis
20%
Heart Arrest
18%
Parkinson's Disease
18%
Randomized Controlled Trial
11%
Atrial Fibrillation
10%
Symptom
10%
Somatomedin C
9%
Brain Derived Neurotrophic Factor
9%
Headache
9%
Armodafinil
9%
Modafinil
9%
Botulinum Toxin B
9%
Hypersalivation
9%
Insulin Receptor Substrate 1
9%
Brain Hemorrhage
9%
Botulinum Toxin
9%
Procoagulant
9%
Sleep Disordered Breathing
9%
Migraine
9%
Levetiracetam
9%
Warfarin
9%
Malignant Neoplasm
9%
Tissue Plasminogen Activator
8%
Botulinum Toxin A
8%
Cross-Validation
7%
Anticoagulant Agent
6%
Diabetes Mellitus
6%
Daytime Somnolence
5%
Neuroprotective Agent
5%
